Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma

• Published in: British journal of cancer Vol. 98; no. 5; pp. 1001 - 1005
• Main Authors: Andersson, A, Enblad, G, Tavelin, B, Björkholm, M, Linderoth, J, Lagerlöf, I, Merup, M, Sender, M, Malmer, B
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.03.2008; Nature Publishing Group
• Subjects: Adolescent; Adult; Age; Aged; Aged, 80 and over; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer and Oncology; Cancer och onkologi; Cancer Research; Cancer therapies; Chemotherapy; Child; Child, Preschool; Clinical Medicine; cohort; Drug Resistance; Epidemiology; Family medical history; Female; Hematologic and hematopoietic diseases; Hematology; Hodgkin Disease - complications; Hodgkin Disease - genetics; Hospitals; Humans; Incidence; Kirurgi; Klinisk medicin; late effect; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma; Male; Medical and Health Sciences; Medical research; Medical sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Middle Aged; Molecular Medicine; Neoplasms - genetics; Neoplasms, Second Primary - epidemiology; Neoplasms, Second Primary - etiology; Oncology; Onkologi; Patients; Radiation therapy; radiotherapy; Risk Factors; second malignancy; Surgery; Surveillance; Tumors; Sweden; radiotherapy; second malignancy; cohort; late effect; Late; Hodgkin disease; Malignant hemopathy; Malignant tumor; Radiotherapy; Lymphoma; Epidemiology; Family story; Cancerology; Treatment; Second cancer; Lymphoproliferative syndrome; Cohort study; Risk factor; Antecedent; Cancer
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/sj.bjc.6604244

This study estimated the risk of second primary malignancies after Hodgkin's lymphoma (HL) in relation to family history of cancer, age at diagnosis and latency, among 6946 patients treated for HL in Sweden in 1965–1995 identified through the Swedish Cancer Register (SCR). First-degree relatives (FDRs) to the HL patients and their malignancies were then ascertained together with their malignancies through the Multi-Generation Registry and SCR. The HL patient cohort was stratified on the number of FDRs with cancer, and standardised incidence ratios (SIRs) of developing SM were analysed. In the HL cohort, 781 SM were observed 1 year or longer after HL diagnosis. The risk for developing SM increased with the number of FDRs with cancer, SIRs being 2.26, 3.01, and 3.45 with 0, 1, or ⩾2 FDRs with cancer, respectively. Hodgkin's lymphoma long-term survivors treated at a young age with a family history of cancer carry an increased risk for developing SM and may represent a subgroup where standardised screening for the most common cancer sites could be offered in a stringent surveillance programme.